Fillipo, Rebecca http://orcid.org/0000-0003-1467-7971
Leblanc, Thomas W.
Plyler, Katelyn E.
Arizmendi, Cara
Henke, Debra M.
Coles, Theresa
Funding for this research was provided by:
U.S. Food and Drug Administration (75F40120C00069)
Article History
Accepted: 11 June 2024
First Online: 18 June 2024
Declarations
:
: TC received study funding from Pfizer and Merck during the conduct of this study, and had a consulting agreement with Regenxbio. TWL has received honoraria for consulting/advisory boards from AbbVie, Agilix, Agios/Servier, Apellis, Astellas, AstraZeneca, Beigene, BlueNote, BMS/Celgene, Genentech, GSK, Lilly, Meter Health, Novartis, and Pfizer; speaking related honoraria from AbbVie, Agios, Astellas, BMS/Celgene, GSK, Incyte, and Rigel; equity interest in Dosentrx and ThymeCare (stock options in privately-held companies); royalties from UpToDate; research funding from AbbVie, American Cancer Society, AstraZeneca, BMS, Deverra Therapeutics, Duke University, GSK, Jazz Pharmaceuticals, the Leukemia and Lymphoma Society, the National Institute of Nursing Research/ National Institutes of Health, and Seattle Genetics.
: This study was conducted in accordance with the Declaration of Helsinki. The study was approved by the Duke University Institutional Review Board (Pro00108611).
: All participants provided informed consent.